Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial
Official title:
Phase I Study on Doxil and SDZ PSC 833 in the Treatment of AIDS-Associated Kaposi's Sarcoma and Other Advanced Malignancies
The rationale for conducting this study lies in the premise that if indeed the reason for a
limited response of Kaposi's sarcoma lesions and other advanced malignancies to chemotherapy
is attributable to a high expression of P-glycoprotein, then, by inhibiting this pump, tumor
kill would be enhanced and response rates as well as duration of responses would also
increase. Doxil is chosen since recent studies have shown that it is superior to combination
chemotherapy with ABV or BV. Doxil is also known to be active in other malignancies such as
breast and ovarian cancer (34,35). PSC 833 is chosen since it has been found to reverse P-gp
in vitro and in vivo, is non-immunosuppressive, and has been shown in recent Phase 1 studies
to be well tolerated.
There are yet no human studies reported on Doxil pharmacokinetics when combined with MDR
modulators. Preclinical data shows that pharmacokinetics of Doxil, unlike free doxorubicin,
is minimally affected by the addition of PSC 833 (36). Enhanced tumor toxicity was observed
when PSC 833 was combined with Doxil. Since doxorubicin, the active agent in Doxil, is
metabolized by the same cytochrome P450, interactions between these 2 agents may have very
significant clinical implications. The purpose of this study is to assess the toxicity and
determine the maximum tolerated dose of Doxil when combined with PSC 833 in the treatment of
AIDS-KS and other advanced malignancies.
Status | Completed |
Enrollment | 14 |
Est. completion date | July 2002 |
Est. primary completion date | July 2002 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
INCLUSION CRITERIA - Histologically documented malignancy refractory to standard treatment or for which no standard treatment exists, or biopsy proven Kaposi's sarcoma with mucocutaneous lesions numbering 10 or more or a documented visceral KS lesion with at least 2 assessable cutaneous lesions. - A life expectancy of >4 months. - Patients with prior chemotherapy and Doxil exposure are eligible - Age >=18 - Karnofsky score of >=70% - Hemoglobin >=8 g/dl, neutrophil count >=1000 cells/ul and platelet count of >=75,000 cells/ul. - Creatinine clearance of .=50 ml/min or creatinine of <=2.0mg/dl, SGOT <=2X the institutional normal and bilirubin <1.5X institutional normal - Written informed consent has been obtained from the patient. EXCLUSION CRITERIA - Pregnant or breast feeding patients as radioactive tracer material and chemotherapy will be used in this protocol. - Active opportunistic infections requiring antibiotic treatment. - Treatment with radiation or electron beam therapy, interferon or cytotoxic therapy within the preceding 4 weeks. - Clinically significant history of congestive heart failure. - Patients who have moderate to severe sensory and motor peripheral neuropathy. - Any patient currently receiving treatment with any of the following agents which cannot be discontinued at a specified time relative to PSC 833 administration. All of these drugs are well substantiated to interact with cyclosporin A: - Agents increasing serum concentrations of CsA The following drugs must not be administered for 48 hours before PSC 833 is started, during the course of its administration, or up to 48 hours after the last dose of PSC 833 in a cycle: Calcium channel blockers: diltiazem, nicardipine, verapamil Antifungals: fluconazole (dose <200 mg/day allowed), itraconazole, ketoconazole Antibiotics: clarithromycin, erythromycin Others: metoclopramide,bromocriptine, danazol - Agents decreasing serum concentrations of CsA The following drugs must not be administered in the 14 days before PSC 833 is started or during the course of its administration. They may be restarted immediately after the last dose of PSC 833: Antibiotics: nafcillin, rifampin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Others: octreotide, ticlopidine - Hypersensitivity to Doxil or cyclosporin A - Any patient, who, in the judgment of the investigator, may not be able to complete this study. |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Washington University School of Medicine | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety profile and tolerability of Doxil in combination with PSC 833 | Each cycle is 2 weeks long and can continue until disease progression, toxicity, or patient decision | Yes | |
Primary | Maximum tolerated dose of Doxil in combination with PSC 833 | Yes | ||
Primary | Dose limiting toxicity of Doxil in combination with PSC 833 | Yes | ||
Secondary | Effects of PSC 833 on Doxil pharmacokinetics | No | ||
Secondary | Confirm the MDR expression with immunohistochemistry and functionally, with 99MTc-sestamibi | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01828775 -
Palliative Care Intervention in Improving Quality of Life, Psychological Distress, and Communication in Patients With Solid Tumors Receiving Treatment
|
N/A | |
Terminated |
NCT01642342 -
Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors
|
Phase 1 | |
Completed |
NCT00002950 -
Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01705548 -
Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis
|
N/A | |
Completed |
NCT02146222 -
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
|
Phase 1 | |
Terminated |
NCT01602627 -
Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies
|
Phase 1 | |
Completed |
NCT01191216 -
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00992303 -
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
|
||
Recruiting |
NCT01137825 -
Registry of Older Patients With Cancer
|
||
Completed |
NCT00924651 -
Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy
|
Phase 3 | |
Completed |
NCT00949949 -
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
|
Phase 1 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Withdrawn |
NCT00937417 -
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT00710632 -
Screening to Predict Weight Loss in Patients With Cancer
|
N/A | |
Completed |
NCT00573690 -
Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT00544596 -
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
|
Phase 1 | |
Active, not recruiting |
NCT00436735 -
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
|
Phase 1 | |
Completed |
NCT00352443 -
S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
|
Phase 1 | |
Completed |
NCT00126620 -
Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors
|
Phase 1 | |
Completed |
NCT00255658 -
Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors
|
Phase 1 |